Lack of Anti-Factor Xa Activity in Umbilical Cord Vein Samples after Subcutaneous Administration of Heparin or Low Molecular Mass Heparin in Pregnant Women

1993 ◽  
Vol 23 (6) ◽  
pp. 314-320 ◽  
Author(s):  
J. Harenberg ◽  
D. Schneider ◽  
L. Heilmann ◽  
H. Wolf
Keyword(s):  
Pregnant Women ◽  
Molecular Mass ◽  
Umbilical Cord ◽  
Subcutaneous Administration ◽  
Factor Xa ◽  
Umbilical Cord Vein

scholarly journals Direct laboratory evidence that pregnancy-induced hypertension might be associated with increased catecholamines and decreased renalase concentrations in the umbilical cord and mother’s blood

2019 ◽  
Vol 43 (2) ◽  
pp. 77-85
Author(s):  
Yakup Baykus ◽  
Sefer Ustebay ◽  
Rulin Deniz ◽  
Kader Ugur ◽  
Şeyda Yavuzkir ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Pregnant Women ◽  
Umbilical Cord ◽  
Enzyme Linked Immunosorbent Assay ◽  
Pregnancy Induced Hypertension ◽  
Induced Hypertension ◽  
Healthy Control ◽  
C 30 ◽  
Body Mass Indexes ◽  
Umbilical Cord Vein

Abstract Background Renalase (RNL) is a controversial enzyme as to whether it oxidizes catecholamines (CAs) (as is generally accepted) in the blood or not. CAs (dopamine [DPMN], epinephrine [EPI] and norepinephrine [NEPI]) are associated with hypertension, including pregnancy-induced hypertension, which occurs in 8–10% of all pregnancies. Therefore, the aim of the study was to compare CAs and renalase concentration in (i) normotensive controls (C), (ii) patients with preeclampsia (PE) and (iii) patients with severe preeclampsia (SPE), which is one of the well-known symptoms of hypertension. Methods This case-control study involved 90 women divided into three groups – 30 C, 30 PE and 30 SPE – whose age and body mass indexes (BMIs) were similar. A total of 270 blood samples (90 maternal samples, 90 umbilical cord artery samples and 90 umbilical cord vein samples) were obtained. CAs and RNL concentrations of the biological samples were measured by enzyme-linked immunosorbent assay (ELISA). Results Comparing the amounts of CAs, RNL and systolic blood pressure (SBP)/diastolic blood pressure (DBP) between healthy control pregnant women and pregnant women with PE and SPE (SBP/DBP was 120/80 mm Hg for C, above 140/90 mm Hg for PE and above 160/110 mm Hg for SPE), the levels of CAs were significantly increased whereas RNL was reduced. The correlation between SBP/DBP and the amount of RNL in pregnant women with PE and SPE was negative. Conclusions These novel results are evidence that hypertension seen in PE and SPE is directly related to increased levels of CAs and reduced RNL concentrations. The use of RNL preparations may be preferred in future to prevent maternal and perinatal morbidity and mortality due to pregnancy-induced hypertension.

scholarly journals Revealing histamine-sensible activity of Wood umbilical cord serum in experiments with ring segments of arteries and umbilical cord vein and with myometrium strips of pregnant women

2021 ◽  
Vol 51 (4) ◽  
pp. 55-60
Author(s):  
V. I. Tsyrkin ◽  
M. L. Sazanova ◽  
S. A. Dvorianskiy ◽  
S. V. Khlybova
Keyword(s):  
Pregnant Women ◽  
Umbilical Cord ◽  
Blood Circulation ◽  
Histamine Receptors ◽  
Obstetric Complications ◽  
Fetal Blood ◽  
Pathological Conditions ◽  
Cord Blood Serum ◽  
Umbilical Cord Vein

In experiments with 60 segments of arteries and 46 segments of the umbilical cord vein of 24 newborns and 35 strips of myometrium of 12 pregnant women, the effect of 100-fold dilutions of cord blood serum (SPK-1: 100) on the contractile effects of histamine (0.01, 0.1 and 1 ϻg l ml). SPK-1: - 100 increased the vasoconstrictor and uterostimulating effects of histamine. H1-histaminosensitizing activity of SPK-1: 100 and the efficiency of activation of H1-histamine receptors of myocytes of the arteries and umbilical cord veins are increased in the presence of obstetric complications. A conclusion was made about the content of endogenous sensitizer H1-histamine receptors (ESGR) in the fetal blood, the level of which increases in the presence of obstetric complications, as well as the possible role of histamine and ESGR in the regulation of fetoplacental blood circulation in conditions of normal and pathological conditions.

Thrombin generation and low-molecular-weight heparin prophylaxis in pregnant women with thrombophilia

2015 ◽  
Vol 113 (02) ◽  
pp. 283-289 ◽  
Author(s):  
Anna Selmeczi ◽  
Rachel E. J. Roach ◽  
Csaba Móré ◽  
Zoltán Batta ◽  
Jolán Hársfalvi ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Pregnant Women ◽  
Low Molecular Weight Heparin ◽  
Thrombin Generation ◽  
Factor Xa ◽  
Peak Effect ◽  
Low Molecular Weight ◽  
Endogenous Thrombin Potential ◽  
Increased Risk ◽  
Optimal Approach

SummaryPregnancy is associated with increased risk of venous thromboembolism, especially in the presence of thrombophilia. However, there is no consensus on the optimal approach for thromboprophylaxis in this population. Recent evidence suggests that thrombin generation correlates with the overall procoagulant state of the plasma. Our aim was to evaluate thrombin generation in a prospective cohort of thrombophilic pregnant women, and investigate the effectiveness of low-molecular- weight heparin (LMWH) prophylaxis in pregnancy. Women with severe (n=8), mild (n=47) and no (n=15) thrombophilia were followed throughout their pregnancies. Thrombin generation was evaluated in each trimester as well as five days and eight weeks postpartum (as a reference category). In women undergoing LMWH prophylaxis, thrombin generation and anti-Factor-Xa activity were measured just before and 4 hours after administration (peak effect). Thrombin generation was determined using Technothrombin TGA assay system. For the analysis, median peak thrombin and endogenous thrombin potential were used. Peak thrombin and endogenous thrombin potential were increased during pregnancy compared to the non-pregnant state with the highest results in the severe thrombophilia group. In women receiving LMWH prophylaxis a decrease was observed in thrombin generation at peak effect but over the progression of pregnancy the extent of this decrease reduced in a stepwise fashion. Our results show that thrombin generation demonstrates the hypercoagulable state in thrombophilic pregnancies. In addition, we found the effect of LMWH prophylaxis to progressively decrease with advancing stages of pregnancy.

scholarly journals Salmon consumption by pregnant women reduces ex vivo umbilical cord endothelial cell activation

2011 ◽  
Vol 94 (6) ◽  
pp. 1418-1425 ◽  
Author(s):  
Lieke WJ van den Elsen ◽  
Paul S Noakes ◽  
Martin A van der Maarel ◽  
Lefkothea-Stella Kremmyda ◽  
Maria Vlachava ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Pregnant Women ◽  
Umbilical Cord ◽  
Cell Activation ◽  
Ex Vivo ◽  
Endothelial Cell Activation

scholarly journals Treatment of Pregnant Women with a Betamimetic and Verapamil Increases the Micronuclei Frequency in Umbilical Cord Blood Lymphocytes

2008 ◽  
Vol 215 (4) ◽  
pp. 363-371 ◽  
Author(s):  
Darko Grujicic ◽  
Olivera Miloševic-Djordjevic ◽  
Slobodan Arsenijevic ◽  
Dragoslav Marinkovic
Keyword(s):  
Cord Blood ◽  
Pregnant Women ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Blood Lymphocytes ◽  
Cord Blood Lymphocytes

Anti-factor Xa Plasma Levels in Pregnant Women Receiving Low Molecular Weight Heparin Thromboprophylaxis

2008 ◽  
Vol 112 (4) ◽  
pp. 884-889 ◽  
Author(s):  
Nathan S. Fox ◽  
S Katherine Laughon ◽  
Samuel D. Bender ◽  
Daniel H. Saltzman ◽  
Andrei Rebarber
Keyword(s):  
Molecular Weight ◽  
Pregnant Women ◽  
Plasma Levels ◽  
Low Molecular Weight Heparin ◽  
Factor Xa ◽  
Low Molecular Weight

scholarly journals WOMAN-PharmacoTXA trial: Study protocol for a randomised controlled trial to assess the pharmacokinetics and pharmacodynamics of intramuscular, intravenous and oral administration of tranexamic acid in women giving birth by caesarean section

2021 ◽  
Vol 6 ◽  
pp. 157
Author(s):  
Monica Arribas ◽  
Ian Roberts ◽  
Rizwana Chaudhri ◽  
Amber Geer ◽  
Danielle Prowse ◽  
...  
Keyword(s):  
Caesarean Section ◽  
Oral Administration ◽  
Tranexamic Acid ◽  
Pregnant Women ◽  
Umbilical Cord ◽  
Controlled Trial ◽  
Maternal Blood ◽  
Oral Solution ◽  
Adult Women ◽  
Intravenous And Oral Administration

Background: Intravenous tranexamic acid (TXA) within 3 hours of birth significantly reduces death due to bleeding in women with postpartum haemorrhage (PPH). Most PPH deaths occur in the first hours after giving birth and treatment delay decreases survival.  One barrier to rapid TXA treatment is the need for intravenous injection. Intramuscular injection and oral solution of TXA would be easier and faster to administer and would require less training. However, the pharmacokinetics (PK), pharmacodynamics and safety of TXA administered by different routes in pregnant women have not been established. The main aim of this study is to ascertain whether IM and oral solution of TXA will be absorbed at levels sufficient to inhibit fibrinolysis in pregnant women. Methods: WOMAN-PharmacoTXA is a prospective, randomised, open label trial to be conducted in Zambia and Pakistan.  Adult women undergoing caesarean section with at least one risk factor for PPH will be included.  Women will be randomised to receive one of the following about 1 hour prior to caesarean section: 1-gram TXA IV, 1-gram TXA IM, 4-grams TXA oral solution or no TXA. Randomisation will continue until 120 participants with at least six post randomisation PK samples are included. TXA concentration in maternal blood samples will be measured at baseline and at different time points during 24 hours after receipt of intervention. Blood TXA concentration will be measured from the umbilical cord and neonate. The primary endpoint is maternal blood TXA concentrations over time. Secondary outcomes include umbilical cord and neonate TXA concentration D-dimer concentration, blood loss and clinical diagnosis of PPH, injection site reactions and maternal and neonate adverse events. Discussion: The WOMAN-PharmacoTXA trial will provide important data on pharmacokinetics, pharmacodynamics and safety of TXA after IV, intramuscular and oral administration in women giving birth by caesarean section. Trial registration: ClincalTrials.gov, NCT04274335 (18/02/2020).

Sign in / Sign up

Export Citation Format

Share Document